Provention Bio to Present at the H.C. Wainwright 24th Annual Global Investment Conference

Rhea-AI Summary

Provention Bio, Inc. (Nasdaq: PRVB) announced its participation in the H.C. Wainwright 24th Annual Global Investment Conference. The virtual presentation is scheduled for September 12, 2022, at 7:00 AM EST. Investors can access the live webcast via the Company's website, where it will also be archived for 30 days. Provention Bio is focused on developing therapies for immune-mediated diseases, including its lead candidate, teplizumab, which has received FDA filing for delaying Stage 3 type 1 diabetes.

RED BANK, N.J., Sept. 6, 2022 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced that management will participate virtually in a corporate presentation at the H.C. Wainwright 24th Annual Global Investment Conference on Monday, September 12^th at 7:00am EST.

The presentation will be webcast live and can be accessed by visiting the Events and Webcasts section of the Company's website: http://investors.proventionbio.com/events. The webcast will be archived on the Company's website for 30 days following the presentation. 

About Provention Bio, Inc.: 

Provention Bio, Inc. (Nasdaq: PRVB) is a biopharmaceutical company focused on advancing the development of investigational therapies that may intercept and prevent debilitating and life-threatening immune-mediated diseases. The Biologics License Application (BLA) for teplizumab, its lead investigational drug candidate, for the delay of progression to Stage 3 clinical type 1 diabetes in at-risk individuals has been filed by the U.S. Food and Drug Administration (FDA). The Company's pipeline includes additional clinical-stage product candidates that have demonstrated in pre-clinical or clinical studies proof-of-mechanism and/or proof-of-concept in other autoimmune diseases, including celiac disease and lupus. Visit www.ProventionBio.com for more information and follow us on Twitter: @ProventionBio.

Internet Posting of Information:

Provention Bio, Inc. uses its website, www.proventionbio.com, as a means of disclosing material nonpublic information and for complying with its disclosure obligations under Regulation F.D. Such disclosures will be included on the Company's website in the "News" section. Accordingly, investors should monitor this portion of the Company's website, in addition to following its press releases, SEC filings and public conference calls and webcasts.

Investor Contact:
Robert Doody, VP, Investor Relations
rdoody@proventionbio.com
484-639-7235

Media Contact:
Kaelan Hollon, VP, Corporate Communications
khollon@proventionbio.com
202-421-4921

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/provention-bio-to-present-at-the-hc-wainwright-24th-annual-global-investment-conference-301618538.html

SOURCE Provention Bio, Inc.

FAQ

What is the date of Provention Bio's presentation at the H.C. Wainwright conference?

Provention Bio's presentation is scheduled for September 12, 2022.

What time will Provention Bio's presentation start?

The presentation will start at 7:00 AM EST.

How can I access the webcast of Provention Bio's presentation?

The webcast can be accessed on Provention Bio's website under the Events and Webcasts section.

What is the focus of Provention Bio, Inc.?

Provention Bio is focused on developing therapies to intercept and prevent immune-mediated diseases.

What is Provention Bio's lead investigational drug candidate?

Provention Bio's lead candidate is teplizumab, aimed at delaying progression to Stage 3 type 1 diabetes.